

# A Randomized, Controlled Trial of ZMapp for Ebola Virus

New England Journal of Medicine

375, 1448-1456

DOI: [10.1056/nejmoa1604330](https://doi.org/10.1056/nejmoa1604330)

Citation Report

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Lutte contre Ebola : Résultats encourageants pour l'essai clinique Pravail. Revue Francophone Des Laboratoires, 2016, 2016, 8.   | 0.0  | 0         |
| 3  | Hitting Ebola, to the power of two. Science, 2016, 354, 284-285.   | 6.0  | 4         |
| 4  | Experimental Therapies for Ebola Virus Disease: What Have We Learned?. Journal of Infectious Diseases, 2017, 215, jiw496.  | 1.9  | 23        |
| 5  | Ebola and Marburg: Out of Africa. , 2017, , 131-154.   |      | 0         |
| 6  | Trial of ZMapp for Ebola Virus Infection. New England Journal of Medicine, 2017, 376, 700-701.   | 13.9 | 7         |
| 7  | Candidate medical countermeasures targeting Ebola virus cell entry. Future Virology, 2017, 12, 119-140.  | 0.9  | 1         |
| 8  | A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface. ACS Infectious Diseases, 2017, 3, 190-198. | 1.8  | 22        |
| 9  | Multivalent Glycosylated Nanostructures To Inhibit Ebola Virus Infection. Journal of the American Chemical Society, 2017, 139, 6018-6025.                                | 6.6  | 104       |
| 10 | Emerging sexually transmitted viral infections: 1. Review of Ebola virus disease. International Journal of STD and AIDS, 2017, 28, 1352-1359.                            | 0.5  | 5         |
| 11 | How to treat Ebola virus infections? A lesson from the field. Current Opinion in Virology, 2017, 24, 9-15.   | 2.6  | 15        |
| 12 | Bayesian randomized clinical trials: From fixed to adaptive design. Contemporary Clinical Trials, 2017, 59, 77-86.   | 0.8  | 33        |
| 13 | Insights from clinical research completed during the west Africa Ebola virus disease epidemic. Lancet Infectious Diseases, The, 2017, 17, e280-e292.                     | 4.6  | 69        |
| 14 | Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.                                  | 13.5 | 145       |
| 15 | Ebolavirus's Foibles. Cell, 2017, 169, 773-775.  | 13.5 | 7         |
| 16 | Public health impact of the 2014-2015 Ebola outbreak in West Africa: seizing opportunities for the future. BMJ Global Health, 2017, 2, e000202.                          | 2.0  | 51        |
| 17 | The ongoing evolution of antibody-based treatments for Ebola virus infection. Immunotherapy, 2017, 9, 435-450.   | 1.0  | 20        |
| 18 | Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine. Lancet, The, 2017, 389, 578-580.   | 6.3  | 3         |
| 19 | Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives. Journal of Law, Medicine and Ethics, 2017, 45, 375-381.                         | 0.4  | 2         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 20 | Discovering Drugs for the Treatment of Ebola Virus. Current Treatment Options in Infectious Diseases, 2017, 9, 299-317.   | 0.8  | 51        |
| 21 | We Can Do Better – Improving Outcomes in the Midst of an Emergency. New England Journal of Medicine, 2017, 377, 1482-1484.  | 13.9 | 13        |
| 22 | How have retrovirus pseudotypes contributed to our understanding of viral entry?. Future Virology, 2017, 12, 569-581.   | 0.9  | 0         |
| 23 | Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends in Molecular Medicine, 2017, 23, 820-830.   | 3.5  | 17        |
| 24 | Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure. Pediatric Clinics of North America, 2017, 64, 1071-1088.                            | 0.9  | 13        |
| 25 | Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody. Immunology Letters, 2017, 190, 289-295.                 | 1.1  | 2         |
| 26 | Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice. Antiviral Research, 2017, 146, 164-173. | 1.9  | 22        |
| 27 | Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome. Journal of Virology, 2017, 91, .   | 1.5  | 22        |
| 28 | Antibody therapies for the prevention and treatment of viral infections. Npj Vaccines, 2017, 2, 19.   | 2.9  | 156       |
| 29 | Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys. Molecular Therapy, 2017, 25, 2323-2331.   | 3.7  | 9         |
| 30 | Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs, 2017, 77, 1935-1966.  | 4.9  | 156       |
| 31 | Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. New England Journal of Medicine, 2017, 377, 62-70.  | 13.9 | 684       |
| 33 | Marburg- and Ebolaviruses. Current Topics in Microbiology and Immunology, 2017, , .   | 0.7  | 4         |
| 34 | Therapeutics Against Filovirus Infection. Current Topics in Microbiology and Immunology, 2017, 411, 263-290.  | 0.7  | 3         |
| 35 | What Recent History Has Taught Us About Responding to Emerging Infectious Disease Threats. Annals of Internal Medicine, 2017, 167, 805.                                     | 2.0  | 33        |
| 36 | A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment. Molecules, 2017, 22, 1777.                             | 1.7  | 28        |
| 37 | Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development. Biosensors, 2017, 7, 49.   | 2.3  | 85        |
| 38 | Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development. Frontiers in Immunology, 2017, 8, 1554.  | 2.2  | 59        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 39 | From hybridomas to a robust microalgal-based production platform: molecular design of a diatom secreting monoclonal antibodies directed against the Marburg virus nucleoprotein. <i>Microbial Cell Factories</i> , 2017, 16, 131. | 1.9  | 45        |
| 40 | Nubia™'s mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola. <i>Reproductive Health</i> , 2017, 14, 157.  | 1.2  | 16        |
| 41 | Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. <i>Reproductive Health</i> , 2017, 14, 172.   | 1.2  | 69        |
| 42 | Improving readiness for recruitment through simulated trial activation: the Adjuvant Steroids in Adults with Pandemic influenza (ASAP) trial. <i>Trials</i> , 2017, 18, 546.  | 0.7  | 3         |
| 43 | Therapeutic Antibodies for Biodefense. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1053, 173-205.  | 0.8  | 7         |
| 45 | Preliminary thoughts on research in medical humanities. <i>BioScience Trends</i> , 2017, 11, 148-151.   | 1.1  | 2         |
| 46 | Plant-made Salmonella bacteriocins salmocins for control of Salmonella pathovars. <i>Scientific Reports</i> , 2018, 8, 4078.  | 1.6  | 31        |
| 47 | Design and evaluation of bi- and trisppecific antibodies targeting multiple filovirus glycoproteins. <i>Journal of Biological Chemistry</i> , 2018, 293, 6201-6211.   | 1.6  | 7         |
| 48 | Monoclonal Antibodies for Emerging Infectious Diseases – Borrowing from History. <i>New England Journal of Medicine</i> , 2018, 378, 1469-1472.   | 13.9 | 108       |
| 49 | ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus. <i>Journal of Infectious Diseases</i> , 2018, 218, 901-910.  | 1.9  | 26        |
| 50 | Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2018, 218, 555-562.                                    | 1.9  | 34        |
| 51 | Rigorous Clinical Trial Design in Public Health Emergencies Is Essential. <i>Clinical Infectious Diseases</i> , 2018, 66, 1467-1469.  | 2.9  | 20        |
| 52 | Reply to Jacob and Colebunders. <i>Clinical Infectious Diseases</i> , 2018, 67, 985-986.  | 2.9  | 0         |
| 53 | A Multi-Source Adaptive Platform Design for Testing Sequential Combinatorial Therapeutic Strategies. <i>Biometrics</i> , 2018, 74, 1082-1094.   | 0.8  | 38        |
| 54 | Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 36-44.  | 2.9  | 12        |
| 55 | Post-exposure treatments for Ebola and Marburg virus infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 413-434.  | 21.5 | 104       |
| 56 | Ebola Infection in Pregnancy: A Global Perspective and Lessons Learned. <i>Clinical Obstetrics and Gynecology</i> , 2018, 61, 186-196.  | 0.6  | 11        |
| 57 | Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice. <i>Journal of Infectious Diseases</i> , 2018, 217, 916-925.                     | 1.9  | 37        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 58 | Management of Ebola Virus Disease in Children. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 201-214.   | 1.9 | 4         |
| 59 | Initiation and publication time-lags of treatment trials for Ebola virus disease. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 28-29.  | 4.6 | 4         |
| 60 | The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. <i>Cell Host and Microbe</i> , 2018, 23, 101-109.e4.   | 5.1 | 40        |
| 61 | Cloning and plantâ€based production of antibody <scp>MC</scp> 10E7 for a lateral flow immunoassay to detect [4â€arginine]microcystin in freshwater. <i>Plant Biotechnology Journal</i> , 2018, 16, 27-38.                    | 4.1 | 19        |
| 62 | What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028902.  | 2.3 | 31        |
| 63 | Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections. <i>Human Gene Therapy</i> , 2018, 29, 452-466.   | 1.4 | 13        |
| 64 | Disaster Preparedness: Biological Threats and Treatment Options. <i>Pharmacotherapy</i> , 2018, 38, 217-234.   | 1.2 | 30        |
| 65 | Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection. <i>Antiviral Research</i> , 2018, 149, 154-163.  | 1.9 | 31        |
| 66 | Treatment-focused Ebola trials, supportive care and future of filovirus care. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 67-76.  | 2.0 | 9         |
| 67 | Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.   | 4.6 | 112       |
| 68 | The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza. <i>Viral Immunology</i> , 2018, 31, 159-173.  | 0.6 | 28        |
| 69 | Vaccines against Ebola virus. <i>Vaccine</i> , 2018, 36, 5454-5459.  | 1.7 | 43        |
| 71 | A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006530. | 1.3 | 5         |
| 72 | Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?. <i>Expert Review of Vaccines</i> , 2018, 17, 1105-1110.  | 2.0 | 14        |
| 73 | InÂVivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. <i>Cell Reports</i> , 2018, 25, 1982-1993.e4.   | 2.9 | 38        |
| 74 | Novel amodiaquine derivatives potently inhibit Ebola virus infection. <i>Antiviral Research</i> , 2018, 160, 175-182.  | 1.9 | 20        |
| 75 | Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, S565-S573.   | 1.9 | 13        |
| 76 | Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. <i>Nature Communications</i> , 2018, 9, 4013.   | 5.8 | 54        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 77 | Performance of different clinical trial designs to evaluate treatments during an epidemic. PLoS ONE, 2018, 13, e0203387.  | 1.1  | 12        |
| 78 | Antibody-mediated protection against Ebola virus. Nature Immunology, 2018, 19, 1169-1178.   | 7.0  | 127       |
| 79 | Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules. Annual Reports in Medicinal Chemistry, 2018, 51, 135-173.  | 0.5  | 12        |
| 80 | Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop. Cell Reports, 2018, 24, 2723-2732.e4.  | 2.9  | 26        |
| 81 | Barriers to supportive care during the Ebola virus disease outbreak in West Africa: Results of a qualitative study. PLoS ONE, 2018, 13, e0201091.   | 1.1  | 19        |
| 82 | Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2018, 48, 284-286.   | 0.2  | 0         |
| 83 | Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trials Communications, 2018, 12, 1-8.   | 0.5  | 81        |
| 84 | Experimental Ebola drugs face tough test in war zone. Nature, 2018, 561, 14-14.   | 13.7 | 3         |
| 85 | Catching Chances: The Movement to Be on the Ground and Research Ready before an Outbreak. Viruses, 2018, 10, 439.   | 1.5  | 6         |
| 86 | Innovation and trends in the development and approval of antiviral medicines: 1987â€“2017 and beyond. Antiviral Research, 2018, 155, 76-88.   | 1.9  | 154       |
| 87 | Engineering Plants for the Future: Farming with Value-Added Harvest. Progress in Botany Fortschritte Der Botanik, 2018, , 65-108.   | 0.1  | 7         |
| 88 | Preventing rural to urban spread of Ebola: lessons from Liberia. Lancet, The, 2018, 392, 279-280.   | 6.3  | 14        |
| 89 | Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks. PLoS Neglected Tropical Diseases, 2018, 12, e0006275.  | 1.3  | 10        |
| 90 | Intermediate Topics in Biostatistics. , 2018, , 383-409.  |      | 1         |
| 91 | Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. Journal of Infectious Diseases, 2018, 218, S672-S678.                                      | 1.9  | 49        |
| 92 | Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs. Journal of Infectious Diseases, 2018, 218, S603-S611.                       | 1.9  | 6         |
| 93 | Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa. Intensive Care Medicine, 2018, 44, 1266-1275.   | 3.9  | 16        |
| 94 | Analysis of CD8 <sup>+</sup> T cell response during the 2013â€“2016 Ebola epidemic in West Africa. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7578-E7586. | 3.3  | 55        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 95  | Ebola Immunity: Gaining a Winning Position in Lightning Chess. <i>Journal of Immunology</i> , 2018, 201, 833-842.   | 0.4  | 19        |
| 96  | Merck vaccine heads Ebola countermeasures. <i>Nature Biotechnology</i> , 2018, 36, 563-565.   | 9.4  | 2         |
| 97  | Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. <i>Immunity</i> , 2018, 49, 363-374.e10.                                   | 6.6  | 61        |
| 98  | Bioemergency Planning. , 2018, , .  |      | 0         |
| 99  | Communicable Diseases and Emerging Pathogens: The Past, Present, and Future of High-Level Containment Care. , 2018, , 1-19.   |      | 1         |
| 100 | Advanced Plant-Based Glycan Engineering. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 81.  | 2.0  | 101       |
| 101 | Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein. <i>Clinical and Experimental Vaccine Research</i> , 2018, 7, 119.                      | 1.1  | 3         |
| 102 | Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. <i>PLoS Pathogens</i> , 2018, 14, e1007204.   | 2.1  | 16        |
| 103 | A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.                                     | 5.1  | 182       |
| 104 | Ebola Virus Disease. , 0, , 521-525.  |      | 0         |
| 105 | A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle. <i>Genome Medicine</i> , 2018, 10, 58.   | 3.6  | 41        |
| 106 | DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. <i>Scientific Reports</i> , 2018, 8, 12459.      | 1.6  | 21        |
| 107 | New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. <i>Chemistry - an Asian Journal</i> , 2019, 14, 3962-3968.  | 1.7  | 166       |
| 108 | How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 1103-1112.               | 2.5  | 23        |
| 109 | Effect of Mass Artesunate-Amodiaquine Distribution on Mortality of Patients With Ebola Virus Disease During West African Outbreak. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz250. | 0.4  | 9         |
| 110 | Serological evidence of Ebola virus exposure in dogs from affected communities in Liberia: A preliminary report. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007614.              | 1.3  | 14        |
| 111 | Therapeutic strategies to target the Ebola virus life cycle. <i>Nature Reviews Microbiology</i> , 2019, 17, 593-606.  | 13.6 | 110       |
| 112 | Assessment of antiviral therapeutics in animal models of Lassa fever. <i>Current Opinion in Virology</i> , 2019, 37, 84-90.   | 2.6  | 4         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 113 | Vitamin A Supplementation Was Associated with Reduced Mortality in Patients with Ebola Virus Disease during the West African Outbreak. <i>Journal of Nutrition</i> , 2019, 149, 1757-1765.                                   | 1.3  | 21        |
| 114 | Plant-Made Antibodies: Properties and Therapeutic Applications. <i>Current Medicinal Chemistry</i> , 2019, 26, 381-395.  | 1.2  | 12        |
| 115 | Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. <i>Nature Medicine</i> , 2019, 25, 1589-1600.   | 15.2 | 92        |
| 116 | Recent Advances in the Diagnosis and Management of Ebola Virus Disease. <i>Clinical Microbiology Newsletter</i> , 2019, 41, 185-189.   | 0.4  | 5         |
| 118 | Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity. <i>BMC Biotechnology</i> , 2019, 19, 64.  | 1.7  | 18        |
| 119 | Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. <i>Vaccines</i> , 2019, 7, 103.  | 2.1  | 15        |
| 120 | Hematological and biochemical parameters for Chinese rhesus macaque. <i>PLoS ONE</i> , 2019, 14, e0222338.   | 1.1  | 15        |
| 121 | New treatments for Ebola virus disease. <i>BMJ: British Medical Journal</i> , 2019, 366, l5371.  | 2.4  | 13        |
| 122 | Targeting the Non-catalytic RVxF Site of Protein Phosphatase-1 With Small Molecules for Ebola Virus Inhibition. <i>Frontiers in Microbiology</i> , 2019, 10, 2145.   | 1.5  | 14        |
| 123 | Differential requirements for Fcγ3R engagement by protective antibodies against Ebola virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20054-20062.                | 3.3  | 45        |
| 124 | Rekombinante Antikörper. , 2019, , .   |      | 1         |
| 125 | International Biological Reference Preparations for Epidemic Infectious Diseases. <i>Emerging Infectious Diseases</i> , 2019, 25, 205-211.   | 2.0  | 11        |
| 126 | Comprehensive Clinical Care for Infants and Children with Ebola Virus Disease. <i>Global Maternal and Child Health</i> , 2019, , 67-85.  | 0.1  | 0         |
| 127 | Ebola therapies: an unconventionally calculated risk. <i>Lancet, The</i> , 2019, 393, 850-852.   | 6.3  | 4         |
| 128 | Current state-of-the-art in plant-based antibody production systems. <i>Biotechnology Letters</i> , 2019, 41, 335-346.   | 1.1  | 63        |
| 129 | Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet, The</i> , 2019, 393, 889-898. | 6.3  | 99        |
| 130 | An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus. <i>PLoS Pathogens</i> , 2019, 15, e1007375.                               | 2.1  | 41        |
| 131 | The evolution of supportive care for Ebola virus disease. <i>Lancet, The</i> , 2019, 393, 620-621.   | 6.3  | 16        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 132 | New and Emerging Infections: a Select Review of Evolving Pathogens. Current Treatment Options in Pediatrics, 2019, 5, 284-292.   | 0.2  | 1         |
| 133 | Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool. Expert Review of Anti-Infective Therapy, 2019, 17, 467-470.  | 2.0  | 80        |
| 134 | Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. BMC Infectious Diseases, 2019, 19, 376.   | 1.3  | 30        |
| 135 | Statistics at FDA: Reflections on the Past Six Years. Statistics in Biopharmaceutical Research, 2019, 11, 1-12.  | 0.6  | 9         |
| 136 | Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses, 2019, 11, 326.   | 1.5  | 478       |
| 137 | Emerging Infectious Diseases and Antimicrobial Resistance (EIDAR). Military Medicine, 2019, 184, 59-65.  | 0.4  | 2         |
| 138 | Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles. , 2019, , 277-310.   |      | 3         |
| 139 | An overview of tolerogenic immunotherapies based on plant-made antigens. Expert Opinion on Biological Therapy, 2019, 19, 587-599.  | 1.4  | 0         |
| 140 | Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nature Microbiology, 2019, 4, 734-747.  | 5.9  | 158       |
| 141 | Achieving cross-reactivity with pan-ebolavirus antibodies. Current Opinion in Virology, 2019, 34, 140-148.   | 2.6  | 18        |
| 142 | Unprecedented Thiocalixarene Fucoclusters as Strong Inhibitors of Ebola cis-Cell Infection and HCMV-gB Glycoprotein/DC-SIGN C-type Lectin Interaction. Bioconjugate Chemistry, 2019, 30, 1114-1126.              | 1.8  | 16        |
| 143 | In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab <sup>2</sup> ) <sub>2</sub> . Journal of Infectious Diseases, 2019, 220, 41-45.                               | 1.9  | 4         |
| 144 | NK Cells Accumulate in Infected Tissues and Contribute to Pathogenicity of Ebola Virus in Mice. Journal of Virology, 2019, 93, .   | 1.5  | 13        |
| 146 | Maximum Containment Infectious Disease Laboratories as an Integral Part of Emergency Preparedness and Emergency Response. , 2019, , 125-144.   |      | 0         |
| 147 | Shifting the Paradigm â€” Applying Universal Standards of Care to Ebola Virus Disease. New England Journal of Medicine, 2019, 380, 1389-1391.  | 13.9 | 19        |
| 149 | Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. Cell Reports, 2019, 27, 172-186.e7.  | 2.9  | 69        |
| 150 | The Special Pathogens Research Network: Enabling Research Readiness. Health Security, 2019, 17, 35-45.   | 0.9  | 11        |
| 151 | Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015â€”A Retrospective Observational Study. Journal of Infectious Diseases, 2019, 220, 195-202. | 1.9  | 38        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 152 | Ebola virus disease. <i>Lancet, The</i> , 2019, 393, 936-948.  | 6.3  | 305       |
| 153 | Ebola Virus Disease. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 953-976.   | 1.9  | 36        |
| 154 | Generation and Characterization of a Mouse-Adapted Makona Variant of Ebola Virus. <i>Viruses</i> , 2019, 11, 987.  | 1.5  | 13        |
| 155 | A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. <i>New England Journal of Medicine</i> , 2019, 381, 2293-2303.   | 13.9 | 1,171     |
| 156 | A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. <i>Science Translational Medicine</i> , 2019, 11, .                     | 5.8  | 21        |
| 157 | Monoclonal Antibody Therapy for Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2019, 381, 2365-2366.  | 13.9 | 52        |
| 159 | The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007787.           | 1.3  | 10        |
| 160 | Expression of the Biologically Active Insulin Analog SCI-57 in <i>Nicotiana Benthamiana</i> . <i>Frontiers in Pharmacology</i> , 2019, 10, 1335.   | 1.6  | 7         |
| 161 | Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?. <i>Trends in Microbiology</i> , 2019, 27, 8-16.  | 3.5  | 32        |
| 162 | Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease. <i>Journal of Virology</i> , 2019, 93, .  | 1.5  | 14        |
| 163 | Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 798-806.   | 1.6  | 18        |
| 164 | Host and Viral Proteins Modulating Ebola and Marburg Virus Egress. <i>Viruses</i> , 2019, 11, 25.  | 1.5  | 28        |
| 165 | Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. <i>Cell Host and Microbe</i> , 2019, 25, 39-48.e5.   | 5.1  | 83        |
| 166 | It Takes a Matured mAb to Treat Ebolavirus Infection. <i>Cell Host and Microbe</i> , 2019, 25, 10-12.  | 5.1  | 1         |
| 167 | Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. <i>EBioMedicine</i> , 2019, 40, 574-582. | 2.7  | 60        |
| 168 | Plant synthetic biology could drive a revolution in biofuels and medicine. <i>Experimental Biology and Medicine</i> , 2019, 244, 323-331.  | 1.1  | 41        |
| 169 | A careful biomedicine? Generalization and abstraction in RCTs. <i>Critical Public Health</i> , 2019, 29, 181-191.  | 1.4  | 16        |
| 170 | Monoclonal antibodies as anti-infective products: a promising future?. <i>Clinical Microbiology and Infection</i> , 2019, 25, 60-64.   | 2.8  | 55        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 171 | Impact of Intravenous Fluid Therapy on Survival Among Patients With Ebola Virus Disease: An International Multisite Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 1038-1047.   | 2.9  | 6         |
| 172 | <i>In vitro</i> and <i>in vivo</i> efficacy of anti-Ebola virus monoclonal antibodies produced in wild-type and glycoengineered <i>Nicotiana benthamiana</i> plants. <i>Plant Biotechnology Journal</i> , 2020, 18, 266-273.                         | 4.1  | 46        |
| 173 | Ebola Virus in the Democratic Republic of the Congo. <i>Chest</i> , 2020, 157, 42-46.  | 0.4  | 9         |
| 175 | Hemorrhagic Fevers. , 2020, , 119-138.   |      | 0         |
| 176 | Association between multivitamin supplementation and mortality among patients with Ebola virus disease: An international multisite cohort study. <i>African Journal of Emergency Medicine</i> , 2020, 10, 23-29.                                     | 0.4  | 4         |
| 177 | Association between treatment with oral third-generation cephalosporin antibiotics and mortality outcomes in Ebola virus disease: a multinational retrospective cohort study. <i>Tropical Medicine and International Health</i> , 2020, 25, 433-441. | 1.0  | 2         |
| 178 | Molecular Farming for low and middle income countries. <i>Current Opinion in Biotechnology</i> , 2020, 61, 53-59.  | 3.3  | 30        |
| 179 | Molecular farming for therapies and vaccines in Africa. <i>Current Opinion in Biotechnology</i> , 2020, 61, 89-95.   | 3.3  | 9         |
| 180 | Ebola virus disease: An emerging and re-emerging viral threat. <i>Journal of Autoimmunity</i> , 2020, 106, 102375.   | 3.0  | 79        |
| 181 | Towards quantification of protective antibody responses by passive transfer of the 1st WHO International Standard for Ebola virus antibody in a guinea pig model. <i>Vaccine</i> , 2020, 38, 345-349.  | 1.7  | 4         |
| 182 | Remdesivir against COVID-19 and Other Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2020, 34, .   | 5.7  | 181       |
| 183 | Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials. <i>Lancet</i> , 2020, 396, 1491-1503. | 6.3  | 132       |
| 184 | To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. <i>Microorganisms</i> , 2020, 8, 1473.   | 1.6  | 12        |
| 185 | Characteristics of Ebola Virus Disease Survivor Blood and Semen in Liberia: Serology and Reverse Transcription Polymerase Chain Reaction (RT-PCR). <i>Clinical Infectious Diseases</i> , 2021, 73, e3641-e3646.                                      | 2.9  | 3         |
| 186 | COVID-19 vaccine development and a potential nanomaterial path forward. <i>Nature Nanotechnology</i> , 2020, 15, 646-655.  | 15.6 | 501       |
| 187 | Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. <i>Seminars in Immunology</i> , 2020, 50, 101427.   | 2.7  | 31        |
| 188 | Pregnant Women in Low- and Middle-Income Countries Require a Special Focus During the COVID-19 Pandemic. <i>Frontiers in Global Women S Health</i> , 2020, 1, 564560.  | 1.1  | 22        |
| 189 | The Emergency Response Capacity of Plant-Based Biopharmaceutical Manufacturing-What It Is and What It Could Be. <i>Frontiers in Plant Science</i> , 2020, 11, 594019.  | 1.7  | 48        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 190 | Monoclonal Antibodies B38 and H4 Produced in <i>Nicotiana benthamiana</i> Neutralize SARS-CoV-2 in vitro. <i>Frontiers in Plant Science</i> , 2020, 11, 589995.  | 1.7  | 51        |
| 191 | Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. <i>Immunologic Research</i> , 2020, 68, 325-339.   | 1.3  | 39        |
| 192 | AAV Vectored Immunoprophylaxis for Filovirus Infections. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 169.   | 0.9  | 11        |
| 193 | Expression of novel lhmlt fusion protein using plant viral vector and study of its anticancer effect. <i>Plant Cell, Tissue and Organ Culture</i> , 2020, 143, 97-108.   | 1.2  | 2         |
| 194 | Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1738-1748.   | 0.6  | 36        |
| 195 | Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3023-3033.   | 1.4  | 8         |
| 196 | A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection. <i>Antiviral Research</i> , 2020, 183, 104932.  | 1.9  | 2         |
| 197 | Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3055-3060. | 1.4  | 68        |
| 198 | Recent successes in therapeutics for Ebola virus disease: no time for complacency. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e231-e237.   | 4.6  | 42        |
| 199 | Understanding P-Values and Confidence Intervals. , 2020, , 280-302.  |      | 0         |
| 200 | Resist the Temptation of Response-Adaptive Randomization. <i>Clinical Infectious Diseases</i> , 2020, 71, 3002-3004.   | 2.9  | 30        |
| 201 | Ebola. <i>New England Journal of Medicine</i> , 2020, 382, 1832-1842.  | 13.9 | 128       |
| 202 | Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China. <i>International Journal of Biological Sciences</i> , 2020, 16, 1846-1860.                      | 2.6  | 56        |
| 203 | Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 226.   | 1.2  | 82        |
| 204 | Combating biothreat pathogens: ongoing efforts for countermeasure development and unique challenges. , 2020, , 171-222.  |      | 0         |
| 205 | Fragment screening targeting Ebola virus nucleoprotein C-terminal domain identifies lead candidates. <i>Antiviral Research</i> , 2020, 180, 104822.  | 1.9  | 3         |
| 206 | Epitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution. <i>Biotechnology Journal</i> , 2020, 15, 2000069.   | 1.8  | 9         |
| 207 | From single-arm studies to externally controlled studies. Methodological considerations and guidelines. <i>Therapie</i> , 2020, 75, 21-27.   | 0.6  | 14        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 208 | Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 258-271.        | 1.3  | 20        |
| 209 | Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. <i>International Journal of Biological Sciences</i> , 2020, 16, 1718-1723.                  | 2.6  | 225       |
| 210 | Treating COVID-19â€™ Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1897. | 3.8  | 396       |
| 211 | Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. <i>F1000Research</i> , 0, 9, 72.   | 0.8  | 37        |
| 212 | Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. <i>New England Journal of Medicine</i> , 2020, 382, 1366-1369.                                   | 13.9 | 63        |
| 213 | Optimised production of an anti-fungal antibody in Solanaceae hairy roots to develop new formulations against <i>Candida albicans</i> . <i>BMC Biotechnology</i> , 2020, 20, 15.          | 1.7  | 9         |
| 214 | In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies. <i>BioDrugs</i> , 2020, 34, 273-293.  | 2.2  | 41        |
| 215 | SARS-CoV-2 neutralizing antibody development strategies. <i>Turkish Journal of Biology</i> , 2020, 44, 203-214.   | 2.1  | 8         |
| 216 | The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2020, 42, 1330-1360.  | 1.1  | 74        |
| 217 | The COVID-19 pandemic. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 365-388.   | 2.7  | 737       |
| 218 | Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020, 32, 107918.  | 2.9  | 148       |
| 219 | COVID-19: has EBM been replaced by hype-based medicine?. <i>Drug and Therapeutics Bulletin</i> , 2020, 58, 99-100.  | 0.3  | 3         |
| 220 | The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008259.   | 1.3  | 13        |
| 221 | Novel viruses, old data, and basic principles: how to save lives and avoid harm amid the unknown. <i>Lancet Respiratory Medicine</i> , 2020, 8, 661-663.                                  | 5.2  | 10        |
| 222 | Prospects for the Production of Recombinant Therapeutic Proteins and Peptides in Plants: Special Focus on Angiotensin I-Converting Enzyme Inhibitory (ACEI) Peptides. , 0, , .            |      | 2         |
| 223 | The 2018/19 Ebola epidemic the Democratic Republic of the Congo (DRC): epidemiology, outbreak control, and conflict. <i>Infection Prevention in Practice</i> , 2020, 2, 100038.           | 0.6  | 14        |
| 224 | Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13.   | 18.1 | 340       |
| 225 | Structural Basis for a Convergent Immune Response against Ebola Virus. <i>Cell Host and Microbe</i> , 2020, 27, 418-427.e4.   | 5.1  | 25        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 226 | Treatment of Ebola-related critical illness. <i>Intensive Care Medicine</i> , 2020, 46, 285-297.  | 3.9 | 15        |
| 227 | Modeling Challenges of Ebola Virusâ€™Host Dynamics during Infection and Treatment. <i>Viruses</i> , 2020, 12, 106.  | 1.5 | 7         |
| 228 | Molecular farming â€™ The slope of enlightenment. <i>Biotechnology Advances</i> , 2020, 40, 107519.   | 6.0 | 116       |
| 229 | Development of an antibody cocktail for treatment of Sudan virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3768-3778.  | 3.3 | 23        |
| 230 | Bayesian statistical methods and their application to resuscitation trials. <i>Resuscitation</i> , 2020, 149, 60-64.  | 1.3 | 3         |
| 232 | Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model. <i>MBio</i> , 2020, 11, .   | 1.8 | 31        |
| 233 | Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. <i>European Journal of Integrative Medicine</i> , 2020, 36, 101116.  | 0.8 | 71        |
| 234 | Engineering the Plant Secretory Pathway for the Production of Next-Generation Pharmaceuticals. <i>Trends in Biotechnology</i> , 2020, 38, 1034-1044.  | 4.9 | 43        |
| 235 | The Plasma Mobile, â€™A gift from heavenâ€™™: The impact of health technology transfer on trial perceptions and expectations during the Ebola-Tx Trial, Conakry. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008206.            | 1.3 | 1         |
| 236 | Ethics of Conducting Clinical Research in an Outbreak Setting. <i>Annual Review of Virology</i> , 2020, 7, 475-494.   | 3.0 | 10        |
| 237 | Antiviral therapies: advances and perspectives. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 305-320.   | 1.0 | 30        |
| 238 | Optimizing clinical research procedures in public health emergencies. <i>Medicinal Research Reviews</i> , 2021, 41, 725-738.  | 5.0 | 5         |
| 239 | Review of Ebola virus disease in children â€™ how far have we come?. <i>Paediatrics and International Child Health</i> , 2021, 41, 12-27.   | 0.3 | 5         |
| 240 | Quantitative proteomic profiling of shake flask versus bioreactor growth reveals distinct responses of <i>Agrobacterium tumefaciens</i> for preparation in molecular pharming. <i>Canadian Journal of Microbiology</i> , 2021, 67, 75-84. | 0.8 | 8         |
| 241 | Multivalent Glycosylated Carbon Nanostructures: Efficient Inhibitors of Emergent Viruses Infection. <i>RSC Nanoscience and Nanotechnology</i> , 2021, , 56-97.  | 0.2 | 2         |
| 242 | Therapeutic targets and potential agents for the treatment of COVIDâ€™19. <i>Medicinal Research Reviews</i> , 2021, 41, 1775-1797.  | 5.0 | 21        |
| 243 | Immune-Based Therapy for COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 449-468.  | 0.8 | 16        |
| 244 | Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2. <i>Antibody Therapeutics</i> , 2021, 4, 60-71.  | 1.2 | 1         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 245 | Analysis of an Ebola virus disease survivor whose host and viral markers were predictive of death indicates the effectiveness of medical countermeasures and supportive care. <i>Genome Medicine</i> , 2021, 13, 5.         | 3.6  | 9         |
| 246 | Use of Immunoglobulins in the Prevention of Viral Infections. , 2021, , 267-280.  |      | 1         |
| 248 | Ebola: A review and focus on neurologic manifestations. <i>Journal of the Neurological Sciences</i> , 2021, 421, 117311.  | 0.3  | 4         |
| 249 | Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 172, 524-541.   | 3.6  | 123       |
| 250 | Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. <i>Immunity</i> , 2021, 54, 412-436.   | 6.6  | 23        |
| 251 | Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response. <i>Pathogens</i> , 2021, 10, 275.  | 1.2  | 3         |
| 252 | Targeting Ebola virus replication through pharmaceutical intervention. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 201-226.  | 1.9  | 11        |
| 253 | Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age. <i>Vaccine</i> , 2021, 39, 1528-1533. | 1.7  | 40        |
| 254 | Antivirals with common targets against highly pathogenic viruses. <i>Cell</i> , 2021, 184, 1604-1620.   | 13.5 | 78        |
| 255 | Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 79-86.  | 3.0  | 9         |
| 256 | In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). <i>Scientific Reports</i> , 2021, 11, 5318.                            | 1.6  | 25        |
| 257 | Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. <i>Vox Sanguinis</i> , 2021, 116, 872-879.   | 0.7  | 8         |
| 258 | Combination therapy protects macaques against advanced Marburg virus disease. <i>Nature Communications</i> , 2021, 12, 1891.  | 5.8  | 37        |
| 259 | Remdesivir: An Antiviral Still Seeking a Raison d'Être. <i>Clinical Infectious Diseases</i> , 2021, 73, 1857-1859.  | 2.9  | 0         |
| 260 | IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008403.                    | 1.3  | 19        |
| 261 | Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021, 40, 36-49.   | 0.8  | 8         |
| 262 | Urgently seeking efficiency and sustainability of clinical trials in global health. <i>The Lancet Global Health</i> , 2021, 9, e681-e690.   | 2.9  | 19        |
| 263 | Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak. <i>BMC Medical Research Methodology</i> , 2021, 21, 98.  | 1.4  | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 264 | Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. <i>Nature Communications</i> , 2021, 12, 2633.   | 5.8 | 25        |
| 265 | Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates. <i>Frontiers in Plant Science</i> , 2021, 12, 682953.  | 1.7 | 44        |
| 266 | Expression and Functional Evaluation of Recombinant Anti-receptor Activator of Nuclear Factor Kappa-B Ligand Monoclonal Antibody Produced in <i>Nicotiana benthamiana</i> . <i>Frontiers in Plant Science</i> , 2021, 12, 683417.   | 1.7 | 5         |
| 267 | Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises. <i>Drug Discovery Today</i> , 2021, 26, 2608-2618.   | 3.2 | 2         |
| 268 | An innovative and integrated model for global outbreak response and research -A case study of the UK Public Health Rapid Support Team (UK-PHRST). <i>BMC Public Health</i> , 2021, 21, 1378.  | 1.2 | 5         |
| 269 | Site-Specific Glycosylation of Recombinant Viral Glycoproteins Produced in <i>Nicotiana benthamiana</i> . <i>Frontiers in Plant Science</i> , 2021, 12, 709344.   | 1.7 | 9         |
| 270 | Antimicrobial immunotherapeutics: past, present and future. <i>Emerging Topics in Life Sciences</i> , 2021, 5, 609-628.   | 1.1 | 1         |
| 271 | Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.   | 1.4 | 6         |
| 272 | Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases. <i>Plant Biotechnology Journal</i> , 2021, 19, 1901-1920.   | 4.1 | 44        |
| 274 | Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. <i>Pathogens</i> , 2021, 10, 1051.   | 1.2 | 18        |
| 275 | Remdesivir inhibits the polymerases of the novel filoviruses Lloviu and Bombali virus. <i>Antiviral Research</i> , 2021, 192, 105120.   | 1.9 | 8         |
| 276 | Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2021, 95, e0079621.  | 1.5 | 6         |
| 277 | Plant-made vaccines and therapeutics. <i>Science</i> , 2021, 373, 740-741.  | 6.0 | 27        |
| 278 | Herramientas biotecnológicas en el diagnóstico, prevención y tratamiento frente a pandemias. <i>Revista Bionatura</i> , 2021, 3, 2091-2113.   | 0.1 | 0         |
| 279 | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. <i>Frontiers in Immunology</i> , 2021, 12, 721328.  | 2.2 | 28        |
| 280 | At-CycD2 Enhances Accumulation of Above-Ground Biomass and Recombinant Proteins in Transgenic <i>Nicotiana benthamiana</i> Plants. <i>Frontiers in Plant Science</i> , 2021, 12, 712438.  | 1.7 | 3         |
| 281 | Low-Valent Calix[4]arene Glycoconjugates Based on Hydroxamic Acid Bearing Linkers as Potent Inhibitors in a Model of Ebola Virus Cis-Infection and HCMV-gB-Recombinant Glycoprotein Interaction with MDDC Cells by Blocking DC-SIGN. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14332-14343. | 2.9 | 5         |
| 282 | Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. <i>Scientific Reports</i> , 2021, 11, 19458.  | 1.6 | 9         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 283 | The challenges with developing therapeutic monoclonal antibodies for pandemic application. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 5-8.   | 2.5 | 2         |
| 284 | Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. <i>Antiviral Research</i> , 2021, 194, 105161.  | 1.9 | 6         |
| 285 | Therapeutics development for Ebola virus disease: A recent scenario. <i>Current Opinion in Pharmacology</i> , 2021, 60, 208-215.  | 1.7 | 12        |
| 286 | Assessing the quality of randomization methods in randomized control trials. <i>Healthcare</i> , 2021, 9, 100570.   | 0.6 | 1         |
| 287 | SpaceHort: redesigning plants to support space exploration and on-earth sustainability. <i>Current Opinion in Biotechnology</i> , 2022, 73, 246-252.  | 3.3 | 21        |
| 288 | Immunological mechanisms associated with clinical features of Ebola virus disease and its control and prevention. , 2021, , 159-183.  |     | 0         |
| 289 | Correlation of Influenza B Haemagglutination Inhibitor, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines. <i>Vaccines</i> , 2021, 9, 100. | 2.1 | 8         |
| 290 | Control of internal validity threats in a modified adaptive platform design using Halili Physical Therapy Statistical Analysis Tool (HPTSAT). <i>MethodsX</i> , 2021, 8, 101232.                                  | 0.7 | 2         |
| 291 | Investigation of a monoclonal antibody against enterotoxigenic <i>Escherichia coli</i> , expressed as secretory IgA1 and IgA2 in plants. <i>Gut Microbes</i> , 2021, 13, 1-14.                                    | 4.3 | 14        |
| 292 | Ebola and Pregnant Women: Providing Maternity Care at MSF Treatment Centers. <i>Global Maternal and Child Health</i> , 2019, , 87-101.  | 0.1 | 2         |
| 293 | Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. <i>Therapie</i> , 2020, 75, 363-370.  | 0.6 | 37        |
| 296 | Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. <i>F1000Research</i> , 2020, 9, 72.  | 0.8 | 251       |
| 297 | Medical research during the COVID-19 pandemic. <i>World Journal of Clinical Cases</i> , 2020, 8, 3156-3163.   | 0.3 | 14        |
| 298 | Quantification of Ebola virus replication kinetics in vitro. <i>PLoS Computational Biology</i> , 2020, 16, e1008375.  | 1.5 | 10        |
| 299 | Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. <i>PLoS Medicine</i> , 2018, 15, e1002535.   | 3.9 | 108       |
| 300 | The natural history of acute Ebola Virus Disease among patients managed in five Ebola treatment units in West Africa: A retrospective cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005700. | 1.3 | 21        |
| 301 | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review. <i>Iranian Journal of Public Health</i> , 2020, 49, 18-29.  | 0.3 | 30        |
| 302 | Transient Production of Recombinant Pharmaceutical Proteins in Plants: Evolution and Perspectives. <i>Current Medicinal Chemistry</i> , 2019, 26, 365-380.  | 1.2 | 41        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 303 | Antibody Therapy for the Control of Viral Diseases: An Update. Current Pharmaceutical Biotechnology, 2019, 20, 1108-1121.  | 0.9 | 27        |
| 304 | Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design. Journal of Epidemiology and Global Health, 2021, 11, 15.  | 1.1 | 4         |
| 305 | Recombinant Antibodies to the Ebola Virus Glycoprotein. Acta Naturae, 2017, 9, 84-91.  | 1.7 | 3         |
| 306 | Advanced Preparation Makes Research in Emergencies and Isolation Care Possible: The Case of Novel Coronavirus Disease (COVID-19). American Journal of Tropical Medicine and Hygiene, 2020, 102, 926-931.                       | 0.6 | 11        |
| 307 | Viral Load in Non-Surviving Liberian Ebola Virus Disease Patients Is Underestimated by Diagnostic qRT-PCR: A Retrospective Observational Study. SSRN Electronic Journal, 0, , .  | 0.4 | 0         |
| 308 | Immunoglobulin A Glycosylation and Its Role in Disease. Experientia Supplementum (2012), 2021, 112, 433-477.   | 0.5 | 7         |
| 309 | Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Human Vaccines and Immunotherapeutics, 2021, 17, 4328-4344.                          | 1.4 | 13        |
| 310 | Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus. Virologica Sinica, 2021, 36, 1600-1610.   | 1.2 | 5         |
| 311 | Society of Internal Medicine, 2017, 106, 405-408.  | 0.0 | 0         |
| 312 | Chapter 17 Plant-Based Production of Biosimilar Drug Products. Drugs and the Pharmaceutical Sciences, 2017, , 439-458.   | 0.1 | 0         |
| 314 | Viral Hemorrhagic Fever Preparedness. , 2018, , 197-211.   |     | 0         |
| 315 | Ebola Hemorrhagic Fever: Recent Update On Disease Status, Current Therapies And Advances In Treatment. Journal of Pharmaceutical Technology Research and Management, 2017, 5, 217-234.   | 0.3 | 1         |
| 316 | Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. SSRN Electronic Journal, 0, , .  | 0.4 | 0         |
| 317 | Ebola Virus Disease in the Obstetric Population. , 2018, , 87-144.   |     | 1         |
| 318 | Faire face à la menace infectieuse en réanimation : de la veille épidémiologique à l'innovation. Actes du séminaire de recherche translationnelle de la Société de réanimation de langue française (5 décembre) ETQq000 rgBT / |     |           |
| 320 | Ebola Virus Disease - clinical manifestations, management and future therapies. Journal of the Royal Naval Medical Service, 2019, 105, 113-120.  | 0.0 | 0         |
| 321 | “They Say My Baby’s Head Is Too Small”, 2019, , 453-475.   |     | 0         |
| 323 | Cancer Clinical Trials Based on Master Protocol. Japanese Journal of Biometrics, 2019, 39, 85-101.   | 0.0 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 324 | Clinical Management of Patients Infected with Highly Pathogenic Microorganisms. , 2019, , 171-194.   |     | 1         |
| 325 | Immunoinformatics Approach Identified Two Highly Conserved B and T Cell Epitopes, LEASKRWAF and DSPLEASKRWAFRTG, for Effective Vaccine Design against Ebola and Marburg Viruses. Journal of Advances in Microbiology, 0, , 1-16. | 0.2 | 0         |
| 326 | Molecular docking enabled updated screening of the matrix protein VP40 from Ebola virus with millions of compounds in the MCULE database for potential inhibitors. Bioinformation, 2019, 15, 627-632.                            | 0.2 | 10        |
| 327 | Ebola virüsüne yönelik ilaçların geliştirilmesi: bir umut. Cukurova Medical Journal, 2019, 44, 1532-1533   |     | 0         |
| 329 | Manufacturing plant-made monoclonal antibodies for research or therapeutic applications. Methods in Enzymology, 2021, 660, 239-263.  | 0.4 | 5         |
| 330 | Treatment of Viral Hemorrhagic Fever in a Well-Resourced Environment. , 2020, , 473-479.   |     | 0         |
| 331 | Cross-Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV. Viruses, 2021, 13, 2231.  | 1.5 | 3         |
| 332 | Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Current Opinion in Virology, 2021, 51, 179-189.  | 2.6 | 7         |
| 333 | Specific Infectious Diseases. , 2023, , 51-146.  |     | 0         |
| 334 | Animal Models of Ebolavirus Infection. Comparative Medicine, 2017, 67, 253-262.  | 0.4 | 33        |
| 335 | Recombinant Antibodies to the Ebola Virus Glycoprotein. Acta Naturae, 2017, 9, 84-91.  | 1.7 | 2         |
| 336 | Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Theranostics, 2022, 12, 1-17.   | 4.6 | 6         |
| 337 | Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review. Journal of Virological Methods, 2022, 300, 114375.   | 1.0 | 2         |
| 338 | SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody. Vaccines, 2021, 9, 1365.  | 2.1 | 14        |
| 339 | Insight of oral vaccines as an alternative approach to health and disease management: An innovative intuition and challenges. Biotechnology and Bioengineering, 2022, 119, 327-346.  | 1.7 | 9         |
| 341 | Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Viruses. RSC Drug Discovery Series, 2021, , 256-279.   | 0.2 | 0         |
| 343 | Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies. RSC Drug Discovery Series, 2021, , 91-120.   | 0.2 | 0         |
| 344 | Reproducibility and flexibility of monoclonal antibody production with <i>Nicotiana benthamiana</i> . MAbs, 2022, 14, 2013594.   | 2.6 | 7         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 345 | Development of plant-made monoclonal antibodies against viral infections. <i>Current Opinion in Virology</i> , 2022, 52, 148-160.   | 2.6  | 19        |
| 346 | Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. <i>Frontiers in Immunology</i> , 2021, 12, 808047.   | 2.2  | 4         |
| 347 | A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. <i>Journal of Infection and Public Health</i> , 2022, 15, 285-292. | 1.9  | 18        |
| 348 | Vaccines against SARS-CoV-2. , 2022, , 201-222.   |      | 0         |
| 349 | Types of Interferons and Their Expression in Plant Systems. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 62-71.   | 0.5  | 5         |
| 350 | Therapeutic Strategies against Ebola Virus Infection. <i>Viruses</i> , 2022, 14, 579.   | 1.5  | 16        |
| 351 | Development and Structural Analysis of Antibody Therapeutics for Filoviruses. <i>Pathogens</i> , 2022, 11, 374.   | 1.2  | 7         |
| 352 | Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. <i>Cell</i> , 2022, 185, 995-1007.e18.  | 13.5 | 26        |
| 353 | Compendium on Food Crop Plants as a Platform for Pharmaceutical Protein Production. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3236.  | 1.8  | 10        |
| 354 | How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. <i>Transfusion</i> , 2022, , .  | 0.8  | 13        |
| 355 | The road to effective and accessible antibody therapies against Ebola virus. <i>Current Opinion in Virology</i> , 2022, 54, 101210.   | 2.6  | 7         |
| 356 | The discovery and development of novel treatment strategies for filoviruses. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 139-149.   | 2.5  | 9         |
| 357 | Ebolavirus: Infection, Vaccination and Control. <i>Molecular Genetics, Microbiology and Virology</i> , 2021, 36, S55-S64.   | 0.0  | 0         |
| 358 | Immunization against severe acute respiratory syndrome Coronavirus 2: an overview. <i>African Health Sciences</i> , 2021, 21, 1574-83.  | 0.3  | 2         |
| 359 | Transient Expression of Glycosylated SARS-CoV-2 Antigens in <i>Nicotiana benthamiana</i> . <i>Plants</i> , 2022, 11, 1093.  | 1.6  | 12        |
| 360 | Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. <i>JCI Insight</i> , 2022, 7, .  | 2.3  | 18        |
| 364 | Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly. <i>Journal of Biological Chemistry</i> , 2022, 298, 102025.   | 1.6  | 4         |
| 365 | A Bayesian Model with Application for Adaptive Platform Trials Having Temporal Changes. <i>Biometrics</i> , 2023, 79, 1446-1458.  | 0.8  | 5         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 366 | <scp>Prepared to Act: Lessons Learned by the Special Pathogens Research Network, Based on Collaborations with the NIAID-Led Adaptive COVID-19 <scp>Treatment Trial</scp>. Health Security, 2022, , .                              | 0.9  | 2         |
| 367 | Regulation of Molecular Farming Products. Methods in Molecular Biology, 2022, , 313-333.  | 0.4  | 7         |
| 368 | Carbohydrate-based drugs launched during 2000~2021. Acta Pharmaceutica Sinica B, 2022, 12, 3783-3821.   | 5.7  | 68        |
| 369 | Evaluation of viral load in patients with Ebola virus disease in Liberia: a retrospective observational study. Lancet Microbe, The, 2022, 3, e533-e542.   | 3.4  | 4         |
| 370 | Understanding COVID-19 Situation in Nepal and Implications for SARS-CoV-2 Transmission and Management. Environmental Health Insights, 2022, 16, 117863022211043.  | 0.6  | 2         |
| 371 | Enhanced HIV SOSIP Envelope yields in plants through transient co-expression of peptidyl-prolyl isomerase B and calreticulin chaperones and ER targeting. Scientific Reports, 2022, 12, .   | 1.6  | 4         |
| 372 | Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe, The, 2022, 3, e683-e692.   | 3.4  | 10        |
| 373 | Biopharmaceutical protein production in plant factories. Climate in Biosphere, 2022, 22, 58-68.   | 0.1  | 0         |
| 374 | The Evolution of Medical Countermeasures for Ebola Virus Disease: Lessons Learned and Next Steps. Vaccines, 2022, 10, 1213.   | 2.1  | 11        |
| 375 | Alterations in Microbiota and Metabolites Related to Spontaneous Diabetes and Pre-Diabetes in Rhesus Macaques. Genes, 2022, 13, 1513.   | 1.0  | 3         |
| 376 | A Review on Edible Vaccines and Biopharmaceutical Products from Plants. Current Pharmaceutical Biotechnology, 2023, 24, 495-509.  | 0.9  | 2         |
| 377 | AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challenge. Molecular Therapy - Methods and Clinical Development, 2022, 26, 505-518.           | 1.8  | 5         |
| 378 | EBOLApred: A machine learning-based web application for predicting cell entry inhibitors of the Ebola virus. Computational Biology and Chemistry, 2022, 101, 107766.  | 1.1  | 4         |
| 379 | Platform Trial Designs. , 2022, , 1455-1485.  |      | 0         |
| 380 | The Diagnostic Accuracy of Rapid Diagnostic Tests for Ebola Virus Disease: a Systematic Review. Clinical Microbiology and Infection, 2022, , .  | 2.8  | 0         |
| 381 | Structure of the Ebola virus polymerase complex. Nature, 2022, 610, 394-401.  | 13.7 | 22        |
| 382 | A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine. Frontiers in Immunology, 0, 13, . | 2.2  | 7         |
| 383 | The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review. PLoS Neglected Tropical Diseases, 2022, 16, e0010889.   | 1.3  | 6         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 384 | Development of Antibody-Based Therapeutics Against West Nile Virus in Plants. <i>Methods in Molecular Biology</i> , 2023, , 211-225.   | 0.4 | 2         |
| 385 | The emergence of travel-related infections in critical care units. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 328-339.  | 1.0 | 1         |
| 386 | Engineering Secretary IgA against Infectious Diseases. , 0, , .  |     | 0         |
| 387 | History and impact of the mouse-adapted Ebola virus model. <i>Antiviral Research</i> , 2023, 210, 105493.  | 1.9 | 1         |
| 388 | A high-throughput single-particle imaging platform for antibody characterization and a novel competition assay for therapeutic antibodies. <i>Scientific Reports</i> , 2023, 13, . | 1.6 | 1         |
| 390 | Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better?. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e253-e258.           | 4.6 | 8         |
| 391 | Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges. <i>Vaccines</i> , 2023, 11, 268.   | 2.1 | 16        |
| 392 | Drug Delivery Options for Treatment of Ebola Infection. , 2023, , 161-191.   |     | 0         |
| 393 | Killer to cure: Expression and production costs calculation of tobacco plant—made cancer—immune checkpoint inhibitors. <i>Plant Biotechnology Journal</i> , 2023, 21, 1254-1269.   | 4.1 | 4         |
| 394 | A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters. <i>Frontiers in Plant Science</i> , 0, 14, .  | 1.7 | 11        |
| 395 | Emerging Pathogenic Viral Infections of the Eye. <i>Annual Review of Vision Science</i> , 2023, 9, 71-89.  | 2.3 | 1         |
| 396 | Modulation of <i>in Vitro</i> SARS-CoV-2 Infection by <i>Stephania tetrandra</i> and Its Alkaloid Constituents. <i>Journal of Natural Products</i> , 2023, 86, 1061-1073.          | 1.5 | 2         |
| 403 | Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.  |     | 0         |
| 404 | Ebola Vaccines. , 2023, , 311-329.e6.  |     | 0         |
| 405 | Passive Immunization. , 2023, , 100-112.e11.   |     | 0         |
| 417 | Ethics of Placebo-Controlled Trials: Historical Analysis Including Experiences During the COVID-19 Pandemic. , 2023, , 195-224.  |     | 0         |
| 418 | Plant Molecular Farming: Concept and Strategies. <i>Concepts and Strategies in Plant Sciences</i> , 2023, , 1-34.  | 0.6 | 0         |
| 419 | Biopharming—'s Growing Pains. <i>Concepts and Strategies in Plant Sciences</i> , 2023, , 349-358.  | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 420 | Biosafety, Risk Analysis, and Regulatory Framework for Molecular Farming in Europe. Concepts and Strategies in Plant Sciences, 2023, , 359-381.                   | 0.6 | 0         |
| 421 | Plant Molecular Pharming: Opportunities, Challenges, and Future Perspectives. Concepts and Strategies in Plant Sciences, 2023, , 35-61.                           | 0.6 | 0         |
| 425 | Ebola and Marburg viruses. , 2024, , 2281-2308.   |     | 0         |
| 426 | Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches. Infectious Diseases and Therapy, 2024, 13, 21-55. | 1.8 | 2         |